Clinical trials
Angiosarcoma clinical trials
Below are recruiting angiosarcoma clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06673628RecruitingPhase 2
Pembrolizumab plus lenvatinib for skin angiosarcoma
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
KashiwaAges 18–85 - NCT07655570RecruitingPhase 2
Ivonescimab for advanced skin angiosarcoma
This trial tests a new drug called ivonescimab for people with advanced skin angiosarcoma that has spread or cannot be removed by surgery. You must have already tried a chemotherapy drug like paclitaxel or docetaxel. The goal is to see if ivonescimab can help shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT04859465RecruitingPhase 2
Paclitaxel plus doxorubicin for advanced, unresectable angiosarcoma
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
Guangzhou, GuangdongAges 18–70 - NCT06375941Recruiting
Watching and learning about early-stage angiosarcoma
This study follows patients with angiosarcoma that has not spread and can be removed with surgery. The goal is to learn more about how this rare cancer behaves and how it is best treated.
Rozzano, MilanoAges Any age - NCT06715579Recruiting
Cardiac Angiosarcoma Global Registry
This study is a global registry for people with a rare heart cancer called cardiac angiosarcoma. It collects information on treatments and outcomes to help doctors better understand the disease and improve care.
YerevanAges Any age - NCT07007273RecruitingPhase 2
Pembrolizumab for advanced skin sarcomas (not angiosarcoma)
This trial is testing a drug called pembrolizumab (Keytruda) for people with advanced soft tissue sarcomas that started in the skin. The goal is to see if this immunotherapy can help shrink or slow the growth of these tumors.
Tampa, FloridaAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT04055220Recruiting
Regorafenib to keep bone cancer from coming back
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
BesançonAges 12 years+ - NCT05607095RecruitingPhase 1
TIL therapy for advanced uveal melanoma and sarcomas
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
Harrison, New YorkAges 18 years+ - NCT05859074RecruitingPhase 1
Testing MQ710 injections alone or with pembrolizumab for advanced cancers
This early-phase study tests MQ710, a medicine given by injection into a reachable tumor, to see how well it can control advanced cancers. Some participants also receive pembrolizumab, an immunotherapy, to help the immune system fight the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05961761RecruitingPhase 2
Testing propranolol plus pembrolizumab for advanced sarcoma
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
AarhusAges 18 years+ - NCT06277154RecruitingPhase 2
MASCT-I plus chemo for first-line advanced soft tissue sarcoma
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
GuangzhouAges 18–70 - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06541652Recruiting
Study of rare liver cancers in France
This study looks at people with rare types of liver cancer to learn more about the disease. If you have one of these rare liver cancers, your information could help doctors understand these cancers better.
AmiensAges 18 years+ - NCT06638931RecruitingPhase 2
Nivolumab for rare solid tumors with high PD-L1
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
Fortaleza, CearáAges 18 years+ - NCT06849986RecruitingPhase 2
Immunotherapy & AI for first-line soft tissue sarcoma
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Birmingham, AlabamaAges 18 years+ - NCT07432932Recruiting
Personalized treatment before surgery for high-risk sarcoma
This trial tests a precision medicine approach by giving targeted therapy before surgery for high-risk soft tissue sarcoma. The goal is to see if matching treatment to your tumor's type can improve outcomes.
LondonAges 18 years+
Hear when a new Angiosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Angiosarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for angiosarcoma?
- Yes. Clin2 currently lists 18 recruiting angiosarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a angiosarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a angiosarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.